Literature DB >> 9268493

The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA.

C Leclerc1, E Dériaud, M Rojas, R G Whalen.   

Abstract

In the present study, we have investigated the T cell response to the HBsAg, normally secreted as multivalent particles, and to beta-galactosidase, a cytoplasmic antigen, delivered as plasmid DNAs. We found that cytokines characteristic of a Th1 phenotype are produced in mice immunized by these plasmid DNAs. Using repeated injections of low doses of purified antigen, we demonstrated that neither prolonged presence of the antigen nor site of immunization resulted in an immune response with characteristics resembling those obtained with DNA-mediated immunization. Analysis of immune responses induced in mice by coinjection of plasmid DNA and beta-galactosidase or HBsAg demonstrated that the coinjected DNA stimulated a Th1 response against the injected antigen. These data therefore strongly suggest that the strong immune response obtained after intramuscular DNA immunization was due to the adjuvant effect of the plasmid DNA which is also responsible for the selective activation of CD4(+) T cells with a Th1 phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9268493     DOI: 10.1006/cimm.1997.1161

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  15 in total

Review 1.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.

Authors:  M J McCluskie; C L Brazolot Millan; R A Gramzinski; H L Robinson; J C Santoro; J T Fuller; G Widera; J R Haynes; R H Purcell; H L Davis
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

4.  DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model.

Authors:  Roberto S Dias; Michelle D Teixeira; Mariana F Xisto; John W O Prates; Jessica D Da Silva; Iago O Mello; Cynthia C Da Silva; Sérgio O De Paula
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

Review 5.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

6.  Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.

Authors:  Wai-Ping Woo; Tracy Doan; Karen A Herd; Hans-Jürgen Netter; Robert W Tindle
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Preexposure of murine macrophages to CpG oligonucleotide results in a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide challenge.

Authors:  T D Crabtree; L Jin; D P Raymond; S J Pelletier; C W Houlgrave; T G Gleason; T L Pruett; R G Sawyer
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.

Authors:  J R Bosarge; J M Watt; D O McDaniel; E Swiatlo; L S McDaniel
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

9.  Chimeric lyssavirus glycoproteins with increased immunological potential.

Authors:  C Jallet; Y Jacob; C Bahloul; A Drings; E Desmezieres; N Tordo; P Perrin
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells.

Authors:  W C Brown; D M Estes; S E Chantler; K A Kegerreis; C E Suarez
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.